Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNAO1 | P09471 | 8/20 | 0.55 |
| ▸ | GNAI3 | P08754 | 7/20 | 0.55 |
| ▸ | GNAI1 | P63096 | 7/20 | 0.55 |
| ▸ | GLB1 | P16278 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8323260 | 0.93 | GNAO1 (0.63) | GNAO1GNAI3GNAI1KCNH2 | |
| SCHEMBL8321108 | 0.91 | GNAO1 (0.67) | GNAO1GNAI3GNAI1KCNH2 | |
| SCHEMBL8324108 | 0.91 | GNAO1 (0.67) | GNAO1GNAI3GNAI1KCNH2 | |
| SCHEMBL8322736 | 0.91 | GNAO1 (0.67) | GNAO1GNAI3GNAI1KCNH2 | |
| SCHEMBL8322298 | 0.91 | GNAO1 (0.67) | GNAO1GNAI3GNAI1KCNH2 | |
| SCHEMBL8325799 | 0.91 | GNAO1 (0.67) | GNAO1GNAI3GNAI1KCNH2 | |
| SCHEMBL8318615 | 0.91 | GNAO1 (0.67) | GNAO1GNAI3GNAI1KCNH2 | |
| SCHEMBL8323545 | 0.91 | GNAO1 (0.67) | GNAO1GNAI3GNAI1KCNH2 | |
| SCHEMBL8324635 | 0.86 | DRD2 (0.47) | GNAO1GNAI3GNAI1 | |
| SCHEMBL17212830 | 0.80 | GNAO1 (0.63) | GNAO1GNAI3GNAI1GLB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1503764-B1 | 5-HT4 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF HEART FAILURE | SERODUS AS (NO) | 2010-01-06 | — | — | EP | claimed |
| EP-1503764-A1 | 5-HT4 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF HEART FAILURE | MEDINNOVA AS (NO) | 2005-02-09 | — | — | EP | claimed |
| WO-2003097065-A1 | 5-HT4 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF HEART FAILURE | MEDINNOVA AS (NO) | 2003-11-27 | — | — | WO | claimed |
| US-5705509-A | Tricyclic heterocyclic compounds as 5-HT4 receptor antagonists | SMITHKLINE BEECHAM PLC (GB) | 1998-01-06 | — | — | US | claimed |
| EP-0681583-B1 | TRICYCLIC HETEROCYCLIC COMPOUNDS AS 5-HT4 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1997-10-22 | — | — | EP | claimed |
| EP-0664806-A1 | HETEROCYCLIC CONDENSED BENZOIC ACID DERIVATIVES AS 5-HT 4? RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1995-08-02 | — | — | EP | claimed |
| EP-0662959-A1 | 5-HT4 ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1995-07-19 | — | — | EP | claimed |
| WO-1994008995-A1 | HETEROCYCLIC CONDENSED BENZOIC ACID DERIVATIVES AS 5-HT4 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1994-04-28 | — | — | WO | claimed |
| CN-101297807-A | The use of 5-HT4 receptor antagonists in the prophylaxis or treatment of certain cardiovascular conditions | GLAXOSMITHKLINE LAB SAS (FR) | 2008-11-05 | — | — | CN | disclosed |
| CN-100413539-C | Use of 5-HT 4 receptor antagonists for the treatment of electrophysiological atrial remodelling | GLAXOSMITHKLINE LAB SAS (FR) | 2008-08-27 | — | — | CN | disclosed |
| US-20080125422-A1 | USE OF 5HT4 RECEPTOR ANTAGONISTS IN THE PROPHYLAXIS OR TREATMENT OF CERTAIN CARDIOVASCULAR CONDITIONS | LABORATOIRE GLAXOSMITHKLINE S A S | 2008-05-29 | — | — | US | disclosed |
| EP-0812321-B1 | PROKINETIC OXADIAZOLES | JANSSEN PHARMACEUTICA NV (BE) | 2008-01-23 | — | — | EP | disclosed |
| US-20070015769-A1 | USE OF 5HT4 RECEPTOR ANTAGONISTS IN THE PROPHYLAXIS OR TREATMENT OF CERTAIN CARDIOVASCULAR CONDITIONS | LABORATOIRE GLAXOSMITHKLINE S.A.S. | 2007-01-18 | — | — | US | disclosed |
| US-20050032866-A1 | The use of 5ht4 receptor antagonists in the prophylaxis or treatment of certain cardiovascular conditions | GLAXO GROUP LIMITED (GB) | 2005-02-10 | — | — | US | disclosed |
| CN-1040436-C | Pharmaceuticals | SMITHKLINE BEECHAM PLC (GB) | 1998-10-28 | — | — | CN | disclosed |
| US-5705509-A | Tricyclic heterocyclic compounds as 5-HT4 receptor antagonists | SMITHKLINE BEECHAM PLC (GB) | 1998-01-06 | — | — | US | disclosed |
| US-5580885-A | FOR TREATMENT OF GASTROINTESTINAL, CARDIOVASCULAR OR NERVOUS SYSTEM DISORDERS | SMITHKLINE BEECHAM P.L.C. (GB) | 1996-12-03 | — | — | US | disclosed |
| EP-0629198-A1 | NITROGEN CONTAINING HETEROCYCLIC COMPOUNDS USEFUL AS PHARMACEUTICALS | SMITHKLINE BEECHAM PLC (GB) | 1994-12-21 | — | — | EP | disclosed |
| WO-1993018027-A1 | NITROGEN CONTAINING HETEROCYCLIC COMPOUNDS USEFUL AS PHARMACEUTICALS | SMITHKLINE BEECHAM PLC (GB) | 1993-09-16 | — | — | WO | disclosed |
| CN-1073173-A | Preparation method as the compound of 5-hydroxytryptamine receptor antagonist | SMITHKLINE BEECHAM PLC (GB) | 1993-06-16 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080125422-A1 | USE OF 5HT4 RECEPTOR ANTAGONISTS IN THE PROPHYLAXIS OR TREATMENT OF CERTAIN CARDIOVASCULAR CONDITIONS | HTR4, TPH1, HTR1A | GNAO1 779/4885GNAI3 990/4885GNAI1 1290/4885 |
| US-20050032866-A1 | The use of 5ht4 receptor antagonists in the prophylaxis or treatment of certain cardiovascular conditions | HTR4, HTR1A, TPH1 | GNAO1 899/4885GNAI3 1166/4885GNAI1 1348/4885 |
| US-20070015769-A1 | USE OF 5HT4 RECEPTOR ANTAGONISTS IN THE PROPHYLAXIS OR TREATMENT OF CERTAIN CARDIOVASCULAR CONDITIONS | HTR4, HTR1A, TPH1 | GNAO1 768/4885GNAI3 995/4885GNAI1 1269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.